Clinical trials: CMV
Cytomegalovirus (CMV) Infections
V160 2-Dose and 3-Dose Regimens in Healthy Cytomegalovirus (CMV) Seronegative Females (V160-002)
This study evaluated the safety, tolerability, and efficacy of the cytomegalovirus (CMV) vaccine (V160) administered in a 2-dose or 3-dose regimen to healthy seronegative women 16 to 35 years of age.
- Trial name
- NCT03486834
- Testing
- V160
- Where
- 95 sites in United States, Australia and 5 more
- Volunteers
- 2,200 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Cytomegalovirus (CMV)
Study of SHP620 (Maribavir) in Healthy Adults
The purpose of this study is to determine how an investigational treatment (maribavir) is handled by the body when administered with two already approved drugs (digoxin and dextromethorphan).
- Trial name
- NCT02775240
- Testing
- Digoxin, Maribavir, Dextromethorphan
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Shire
CMV
Detection of Cytomegalovirus Virus in Neonates
To evaluate the illumigene CMV assay, using the illumipro-10 with neonates (up to 21 days of age) saliva swabs
- Trial name
- CMV (NCT03251261)
- Testing
- illumigene CMV assay, illumipro-10
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 1,615 people, healthy volunteers welcome
- Sponsor
- Meridian Bioscience, Inc.